Endpoints in the treatment and management of adults with growth hormone (GH) deficiency (GHD) can be problematic. Changes in body composition with recombinant human GH (rhGH) treatment may be one of the most objective measures that could be applied in judging the effectiveness and long-term efficacy. The relative strengths and weaknesses of measures of body composition and their potential for clinical utility in the setting of rhGH replacement in GHD in adults are discussed. Measurement of changes in body fat, regardless of the method employed, from pretreatment baseline through 2–6 months of treatment may be quite useful in demonstrating the efficacy of rhGH in each patient. Other changes in body composition are compromised by the imprecision of the measurements, shifts in extracellular water, and the small real changes which occur in bone and muscle in the GHD subject. Use of body composition measures of change in fat content as an endpoint in determining the efficacy of rhGH treatment in adults with GHD cannot be implemented on the basis of current data and would require a carefully designed prospective, controlled study. Until such criteria are established and accepted, endocrinologists must continue to manage these patients purely on the basis of their clinical judgment.

Keywords:
rhGH, Methods in measuring body composition
1.
Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A: Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab 1997;82:418–420.
2.
Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P, Johanson AJ: Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 1998;132:319–324.
3.
Haffner D, Wuhl E, Schaefer F, Nissel R, Tönshoff B, Mehls O: Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure: J Am Soc Nephrol 1998;9:1899–1907.
4.
Mehls O, Wuhl E, Haffner D, Schaefer F, Tönshoff B: Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Nephrol Dial Transplant 1996;11:1747–1750.
5.
Rosén T, Bengtsson B-Å: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–288.
6.
Russell-Jones DL, Weissberger AJ, Bowes SB, Kelly JM, Thomason M, Umpleby AM, Jones RH, Sönksen PH: Protein metabolism in growth hormone deficiency, and effects of growth hormone replacement therapy. Acta Endocrinol (Copenh) 1993;128(suppl 2):44–47.
7.
Salomon F, Cuneo RC, Hesp P, Sönksen PH: The effects of treatment of recombinant human growth hormone on body composition and metabolism is adults with growth hormone deficiency. N Engl J Med 1989;321:1797–1803.
8.
Jørgensen JOL, Thuesen L, Muller J, Ovesen P, Skakkebæk NE, Christiansen JS: Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994;130:224–228.
9.
Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH: Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991;70:688–694.
10.
Wirén L, Bengtsson B-Å, Johannsson G: Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol 1998;48:613–620.
11.
Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson B-Å: Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997;82:2877–2884.
12.
Lucidi P, Lauteri M, Laureti S, Celleno R, Santoni S, Volpi E, Angeletti G, Santeusanio F, De Feo P: A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 1998;83:353–357.
13.
Growth Hormone Research Society: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379–381.
14.
Roche AF, Heymsfield SB, Lohman TG (eds): Human Body Composition, Human Kinetics. Champaign, Ill., 1996.
15.
Ellis KJ: Human body composition: in vivo methods. Physiol Rev. In press.
16.
Zi-Mian W, Pierson RN Jr, Heymsfield SB: The five-level model: a new approach to organizing body-composition research. Am J Clin Nutr 1992;56:19–28.
17.
Deurenber P, Schutz Y: Body composition: overview of methods and future directions of research. Ann Nutr Metab 1995;39:325–333.
18.
Pierson RN Jr, Wang J, Thornton JC: Measurement of body composition: applications in hormone research. Horm Res 1997;48(suppl 1):56–62.
19.
Møller J, Frandsen E, Fisker S, Jørgensen JOL, Christiansen JS: Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study. Clin Endocrinol 1996;44:533–539.
20.
Hoffman DM, Crampton L, Sernia C, Nguyen TV, Ho KKY: Short term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab 1996;81:1123–1128.
21.
Jørgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221–1225.
22.
Amato G, Carella C, Fazio S, Montagna GL, Cittadini A, Sabatini D, Marciano-Mone C, Saccà L, Bellastella A: Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993;77:1671–1676.
23.
Bengtsson B-Å, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosæus I, Tölli J, Sjöström L, Isaksson OGP: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309–317.
24.
Carroll PV, Christ ER, and the members of the Growth Hormone Research Society Scientific Committee (Bengtsson B-Å, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorner M): Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998;83:382–395.
25.
Horber FF, Marsh HM, Haymond MW: Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 1990;40:141–149.
26.
Horber FF, Haymond MW: Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990;86:265–272.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.